CLM-022 / Celloram, Genfit - LARVOL DELTA

Therapeutic potential of CLM-022, an inhibitor of NLRP3 inflammasome-mediated pyroptosis, for acute and chronic inflammatory liver diseases (FFS-AIH 2025) - "In preclinical models, the investigational drug CLM-022 disrupts both the priming and activation of the NLRP3 inflammasome and thus demonstrates its therapeutic potential for the treatment of acute and chronic inflammatory liver diseases, including acute-on-chronic liver failure (ACLF)."

Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • GLI2 • IL18 • IL1B • NLRP3

EFFICACY OF THE CLM-022, AN INHIBITOR OF THE NLRP3 INFLAMMASOME, IN IN VIVO AND IN VITRO PATHOGEN-ASSOCIATED MOLECULAR PATTERNS (PAMPS)-INDUCED DISEASE MODELS (AASLD 2025) - "Although further experiments are needed to fully understand how CLM-022 improved survival in septic mice, at a minimum, it seems to be mediated by regulation of the innate immune response. These results further support the development of CLM-022 in advanced liver disease including ACLF"

Preclinical • Fibrosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Septic Shock • IL18 • IL1B • IL6 • NLRP3 • TNFA

GENFIT to Present Latest ACLF Research at EASL Congress 2025 (GlobeNewswire) - "GENFIT...announces its participation at the European Association for the Study of the Liver (EASL) Annual Congress 2025 with six posters presenting the latest research in ACLF and multiple events highlighting the growing importance of ACLF within the hepatology community."

Clinical data • Hepatology • Inflammation • Liver Failure • Metabolic Dysfunction-Associated Steatohepatitis

CLM-022, a dual inhibitor of priming and activation steps of NLRP3 inflammasome, as a potential treatment for acute and chronic inflammatory late-stage liver diseases (EASL 2025) - "Investigational drug CLM-022 is a dual inhibitor of inflammasome expression and activity with nanomolar activity. It enables disruption of both the priming and activation steps of NLRP3 activity and thus, as a dual inhibitor, demonstrates therapeutic potential for the treatment of acute and chronic inflammatory late-stage liver diseases, including ACLF."

Hepatology • Inflammation • Liver Failure • GLI2 • IL18 • IL1B • NLRP3

CLM-022, A POTENT INHIBITOR OF NLRP3 INFLAMMASOME-MEDIATED PYROPTOSIS, AS A POTENTIAL TREATMENT FOR ACUTE AND CHRONIC INFLAMMATORY LIVER DISEASES (AASLD 2024) - "There are currently no approved treatments that act directly on the underlying key pathophysiologic mechanisms that lead to liver failure, such as the systemic inflammatory response. Understanding the underlying molecular and regulatory mechanisms in inflammation and inflammatory cell death that might be involved in the progression of diseases will help to develop novel highly demanded therapies. CLM022, by inhibiting IL1-β production and pyroptosis through its activity on NLRP3, has potential for the treatment of acute and chronic inflammatory liver diseases, including ACLF."

Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • Systemic Inflammatory Response Syndrome • GLI2 • IL18 • IL1B • NLRP3